#Oncology

🏢Release 📈 Stocks

Johnson & Johnson Oncology Data Shows 62% Risk Reduction in Prostate Cancer

October 24, 2026 (10 days ago)

Johnson & Johnson shares gain momentum as new clinical data confirms ERLEADA plus ADT significantly reduces metastasis and mortality risks in prostate…

JNJ

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Orion and Bayer Report 58% Metastasis Risk Reduction in Prostate Cancer Trial

October 24, 2026 (10 days ago)

Phase III data for darolutamide shows a 58% reduction in metastasis risk for high-risk prostate cancer patients, bolstering the clinical outlook for…

ORNBV BAYN

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Eli Lilly Reports 79% Response Rate for Ovarian Cancer Drug Candidate

October 24, 2026 (10 days ago)

Eli Lilly's sofetabart mipitecan shows strong clinical efficacy in ovarian cancer trials, achieving a 100% disease control rate in combination therapy.

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Jazz Pharmaceuticals Reports 40% Three-Year Survival Rate for Ziihera Combo

October 23, 2026 (10 days ago)

Jazz Pharmaceuticals and partner BeiGene report a 27-month median overall survival for Ziihera-based regimens in HER2+ gastroesophageal cancer, bolstering the case for…

JAZZ BGNE

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Florida Cancer Specialists Presents 10 Research Abstracts at ESMO 2026

October 23, 2026 (11 days ago)

Florida Cancer Specialists & Research Institute will showcase 10 clinical research abstracts at the upcoming ESMO Congress 2026, underscoring its active role…

FCS

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Presents Phase 1 Data for ATNM-400 at ESMO 2026

October 23, 2026 (11 days ago)

Actinium Pharmaceuticals showcases its HER3-targeted alpha radiotherapy, ATNM-400, in a Phase 1 study targeting metastatic castration-resistant prostate cancer at the ESMO 2026…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Innovent Biologics Phase 3 Trial Hits Primary Endpoints for Gastric Cancer

October 23, 2026 (11 days ago)

Innovent Biologics' G-HOPE-001 trial confirms clinical efficacy for its ADC candidate, marking a major milestone for the company's oncology pipeline and potential…

01801.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks

Bristol-Myers Squibb Combination Therapy Cuts Disease Progression Risk by 27%

October 23, 2026 (11 days ago)

Bristol-Myers Squibb reports positive clinical trial results as a combination therapy featuring nivolumab reduces disease progression risk by 27% with a median…

BMY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Hengrui Pharma Secures 64 ESMO 2026 Abstracts to Bolster Oncology Pipeline

October 21, 2026 (13 days ago)

Hengrui Pharma strengthens its oncology portfolio as 64 abstracts, including key proffered papers on HER2 and HER3 antibody-drug conjugates, are accepted for…

600276.SS

🌍 ASIA Read More →

🏢Release 📈 Stocks

Hengrui Pharma Shares 64 Research Findings at ESMO 2026 Oncology Conference

October 21, 2026 (13 days ago)

Hengrui Pharma secures 64 research presentations at ESMO 2026, showcasing significant progress in its oncology pipeline with a focus on HER2- and…

600276.SS

🌍 ASIA Read More →

🏢Release 📈 Stocks

Sun Pharma Gains NCCN Category 2A Designation for UNLOXCYT in laCSCC

October 20, 2026 (13 days ago)

Sun Pharma secures NCCN Category 2A Preferred Designation for UNLOXCYT in treating laCSCC, marking a key clinical milestone that strengthens the drug's…

SUNPHARMA

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

Florida Cancer Specialists Adds Surgical Oncologist Kelly Elleson in Fort Myers

October 19, 2026 (14 days ago)

Florida Cancer Specialists & Research Institute appoints Dr. Kelly Elleson to its Fort Myers Colonial office, bolstering regional surgical oncology capabilities for…

🌍 AMERICAS Read More →